Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965469 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ANPC1CYP2C19USP30 | |
| SCHEMBL19023251 | 0.90 | BCHE (0.49) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL19037343 | 0.90 | BCHE (0.49) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL19023252 | 0.90 | BCHE (0.49) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL19023253 | 0.90 | BCHE (0.49) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL13449383 | 0.90 | BCHE (0.49) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL19015604 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL13162568 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL13162565 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9ANPC1CYP2C19KMT2A | |
| SCHEMBL6119752 | 0.84 | MEN1 (0.46) | CYP2C19KMT2AMEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987251-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8575145-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2334677-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 4457/4885RAB9A 2050/4885NPC1 4398/4885 |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | SMN1; SMN2 3338/4885RAB9A 2978/4885NPC1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.